Nanorobotics is a pre-clinical stage, biotechnology company developing and commercializing the Molecular NanoMachines technology for molecular mechanical therapy of cancer.

Nanorobotics platforms leverage the unique characteristics of MNMs, which can drill mechanically through the cell membrane, to develop a pipeline of safe and effective molecular therapies for treating cancers that have shown resistance to conventional therapies.

In several publications, we have demonstrated our potent proprietary cell-killing machinery. Our current focus is indications for oncology, but we are seeking outlicensing agreements to bring this novel technology to other areas, including dermatology, ophthalmology, and cardiology.

Nanorobotics is headquartered in Hod Hasharon, Israel.